Once the debt is completely repaid & we know what the net profit is per year we should not sell for less than 10x that. The profits are mostly recurring revenue from storage fees which will be steadily getting more and more. That is not even taking into account growth & potential in the biotech field overall. We shouldn't settle for anything less than 10x yearly profits.
News 
Market Data 
Discover 
